A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous Treatment

NCT06539338 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphomas Non-Hodgkin's B-Cell
Precursor Cell Lymphoblastic Leukemia-Lymphoma

Interventions

GENETIC: INT2104

Sponsor

Kite, A Gilead Company